Communities in the Amajuba District of KwaZulu-Natal have expressed optimism and relief following the introduction of a new HIV prevention injection that only needs to be administered twice a year. The long-acting injectable, known as Lenacapavir, is being hailed as a major breakthrough in the fight against HIV, particularly for people who struggle to take daily prevention pills consistently.
The injection was officially introduced during a community outreach programme led by KwaZulu-Natal Health MEC Nomagugu Simelane as part of the *Isibhedlela Kubantu* initiative. The programme focuses on taking healthcare services directly to communities, ensuring that people have access to information, screening, and treatment without barriers.
Lenacapavir offers protection against HIV through a single injection given once every six months, making it a practical alternative to daily oral pre-exposure prophylaxis (PrEP). Health officials believe the new method will significantly improve adherence to HIV prevention, especially among individuals who find daily medication difficult due to busy lifestyles, fear of stigma, or concerns about privacy.
Speaking to community members, MEC Simelane said the injection represents hope for many people who have long wanted a simpler and more discreet way to protect themselves from HIV. She explained that missed doses of daily pills reduce effectiveness, while a twice-yearly injection helps ensure continuous protection.
“This injection gives people another choice,” Simelane said. “When people have options that fit their lives, they are more likely to stay protected.”
The HIV prevention injection does not replace other preventive measures such as condoms or regular testing but forms part of a broader combination prevention strategy. Health officials continue to encourage individuals to use multiple prevention tools for maximum protection.
The rollout of the injection in Amajuba is part of a phased approach that will gradually expand to other districts. Wider availability is expected in early 2026, with priority given to areas with high HIV infection rates. South Africa is among the first countries in Africa to register the injection for HIV prevention, marking a significant milestone in public health.
During the outreach event, the Department of Health also urged people living with HIV who have stopped treatment to return to care. Officials warned that treatment interruptions remain a major challenge, particularly during holiday periods. The *Close the Gap* campaign aims to re-engage patients and ensure uninterrupted access to life-saving antiretroviral treatment.
Community members welcomed the new injection with enthusiasm. Some residents said daily pills were difficult to manage, while others said they feared being judged or questioned when seen taking medication. The injection, they said, offers peace of mind and convenience.
Health authorities believe the long-acting HIV prevention injection could play a crucial role in reducing new infections, especially among young people, women, and other high-risk groups. As awareness grows and access expands, communities hope the new tool will help turn the tide against HIV and strengthen efforts toward a healthier future for all.
